Table 3 Clinical trials of protein nanoparticles applied for cancer therapy
From: Protein nanoparticles directed cancer imaging and therapy
Protein nanoparticles | Tumor type | Clinical studies | Year | Database (ID) |
|---|---|---|---|---|
Albumin | Lung cancer | ABI-007 in Treating Patients with Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer | 2003–2008 | ClinicalTrials.gov (NCT00077246) |
Albumin | Ovarian cancer, fallopian tube cancer, and peritoneal cancer | Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy | 2006–2011 | ClinicalTrials.gov (NCT00466960) |
Albumin | Solid tumors | Recombinant EphB4-HSA Fusion Protein with Standard Chemotherapy Regimens in Treating Patients with Advanced or Metastatic Solid Tumors | 2015- | ClinicalTrials.gov (NCT02495896) |
Albumin | Breast cancer | Romidepsin and Abraxane in Treating Patients with Metastatic Inflammatory Breast Cancer | 2014–2016 | ClinicalTrials.gov (NCT01938833) |
Albumin | Pancreatic cancer | Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer | 2014- | ClinicalTrials.gov (NCT02178436) |
Albumin | Melanoma | ABI-007 in Treating Patients with Inoperable Locally Recurrent or Metastatic Melanoma | 2004–2010 | ClinicalTrials.gov (NCT00081042) |